New Report Provides Expert Analysis Of Recent Advances And Setbacks In Parkinson's Disease Drug Development
MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for Parkinson's disease (PD) therapies. This report, entitled Thought Leader Insight & Analysis -- Parkinson's Disease, is based on 9 interviews conducted with PD experts from the US (6) and Europe (3).
"Regardless of whether they're delivered via surgical implants, gene therapies, viral vectors or old-fashioned small molecules, the most dramatic advances in Parkinson's disease therapeutics will be used in early stage disease to prevent loss of functional status and quality of life," says lead author Dr. Jeffrey D. Berk. "Improvements in invasive procedures and new understanding of the pathophysiology of Parkinson's disease are shifting the risk/benefit ratio and opening up new possibilities for patients."
In addition to discussing recent treatment goals, available therapeutic approaches and unmet needs, MedPredict's expert panel explores the current state of the art in new approaches being developed for the symptomatic treatment and disease modification of PD, including:
- Unmet needs: dopamine agonists, wearing off vs. dyskinesia, depression, pain, dementia, psychosis, neuroprotection, impulse control (punding), restless legs syndrome;
- Deep brain stimulation (risk/benefit, pharmacoeconomics);
- Gene therapies and growth factors (human fetal implants, GDNF, neurturin, neublastin, GAD/glutamic acid decarboxylase), alpha-synuclein;
- Dopamine agonists, monoamine oxidase inhibitors;
- Levodopa formulations, COMT inhibitors; and
- Adenosine A2A receptor antagonists, cholinesterase inhibitors, AMPA, 5-HT, anticonvulsants, antihypertensives, farnesyl transferase inhibitors.
Companies mentioned in this report include: Acadia, Amersham Pharmacia Biotech/GE Healthcare, Amsterdam Molecular Therapeutics, Bayer-Schering, Bayer-Schering/Titan, Boehringer Ingelheim, Ceregene/Genzyme, Eisai, Elan, Forest, GlaxoSmithKline, GSK/XenoPort/Astellas, Ipsen, Kyowa, Lilly, Link Medicine Corp, Medtronic, Merck-Serono, Merck-Serono/Newron, NeuroDerm, Neurologix, Novartis, NsGene, Ortho-McNeill-Janssen, Pfizer, Qrx Pharma, Schering-Plough, Solvay, Solvay/Wyeth, Teva, UCB, Valeant, and Wyeth.
This report can be purchased by contacting MedPredict (http://www.medpredict.com/).
About MedPredict
MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.
SOURCE: MedPredict Market Research